Key statistics
As of last trade, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) traded at 16.62, 11.32% above the 52 week low of 14.93 set on Nov 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.01 |
---|---|
High | 17.07 |
Low | 16.20 |
Bid | 16.55 |
Offer | 16.63 |
Previous close | 17.07 |
Average volume | 616.40k |
---|---|
Shares outstanding | 27.09m |
Free float | 24.80m |
P/E (TTM) | -- |
Market cap | 462.38m USD |
EPS (TTM) | -2.33 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:30 GMT.
More ▼
- Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
- Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
- Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
- Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
- Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
- Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
- Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
More ▼